Artera announced on May 6, 2026 that it has received FDA clearance for ArteraAI Breast, which the company calls the first and only FDA-cleared digital pathology-based risk-stratification test for early-stage, hormone receptor-positive, HER2-negative breast cancer. The clearance follows CE marking secured in the European Union on April 21 for both the breast test and Artera’s earlier prostate cancer assay, giving the company regulatory sign-off on two continents within a three-week span.
How the test works
Unlike genomic tests such as Oncotype DX, which require sending additional tumor tissue to a lab for RNA sequencing, ArteraAI Breast generates its risk score directly from digitized histopathology images already produced during routine biopsy, combined with standard clinical variables like tumor grade and size. Because it does not require extra tissue sampling, Artera says results can be integrated into a pathologist’s existing workflow and reported the same day, stratifying patients into low- and high-risk groups for distant metastasis. The company presented supporting data at the San Antonio Breast Cancer Symposium in December 2025, showing the model’s potential to inform which patients are likely to benefit from adding chemotherapy to hormone therapy.
Executives and clinicians react
“This FDA clearance represents a significant expansion of our FDA-cleared AI platform” across cancer types, Artera co-founder and CEO Andre Esteva said in the company’s announcement, framing the breast test as a follow-on to the company’s earlier prostate cancer clearance. Eric Winer, MD, of Yale Cancer Center, called the decision “an important advance on the road to personalizing treatments for patients with early-stage breast cancer,” a sentiment echoed by oncologists who have pushed for years to reduce reliance on genomic assays that can take one to two weeks to return results and cost several thousand dollars per test.
The bigger prognostic-testing market it is entering
Breast cancer risk stratification is a crowded, high-stakes market. Oncotype DX and MammaPrint have dominated for over a decade, guiding chemotherapy decisions for hundreds of thousands of HR+/HER2- patients annually — the single largest breast cancer subtype. Artera’s pitch is speed and cost: an image-based model built on pathology slides that labs already generate, rather than a send-out genomic assay. The company built its reputation first in prostate cancer, where its multimodal AI test has been used to help guide radiation and hormone therapy decisions, and the breast clearance represents its attempt to replicate that model in a second, larger cancer type.
Reasons for caution
Pathologists and biostatisticians who have followed image-based risk models urge caution before ArteraAI Breast is treated as a drop-in replacement for genomic testing. FDA clearance via the 510(k) pathway establishes safety and a reasonable expectation of equivalence to a predicate device, not proof that the tool improves long-term outcomes when used to actually change treatment decisions — that kind of prospective, outcomes-linked validation typically takes years and larger multi-site trials. Critics also note that image-based AI models can be sensitive to differences in how slides are stained and scanned across different labs, a variability problem that genomic assays, which measure gene expression numerically, are less prone to.
How it fits the broader digital pathology wave
Artera’s clearance arrived in the same stretch of 2026 as Leica Biosystems’ quality-control AI clearance and Labcorp’s nationwide rollout of PathAI’s AISight Dx platform, underscoring how quickly digital pathology has moved from a niche academic pursuit to a commercial FDA-regulated category. Where PathAI and Leica are focused on the scanning and quality layer of pathology, Artera is staking its claim on the prognostic layer — turning existing slides into treatment-guiding risk scores.
What happens next
Artera says it plans to pursue additional cancer-type expansions of its multimodal platform beyond prostate and breast, and the company’s next test will likely need real-world adoption data from pathology labs and oncology practices to prove it can compete against entrenched genomic assays on cost and turnaround time. Payers, not just regulators, will ultimately decide the test’s fate: reimbursement decisions from Medicare and private insurers over the next 12 to 18 months will determine whether ArteraAI Breast becomes a routine part of early-stage breast cancer workups or remains a niche alternative alongside better-established genomic tests. Oncology groups will also be watching whether Artera publishes prospective outcomes data showing the test changes treatment decisions in ways that improve survival, rather than simply agreeing with risk factors clinicians already track by hand.
